Skip to content
HowShorted

Citius Pharmaceuticals, Inc. short interest in 2022

In 2022, Citius Pharmaceuticals, Inc.'s disclosed short interest ran from 7.75% of shares outstanding on 14 Jan 2022 to 7.50% on 30 Dec 2022, a change of -0.25 percentage points. The year's high was 10.26% on 31 May 2022 and its low 6.12% on 28 Feb 2022, averaging 7.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 31.17 days on 15 Nov 2022. Full history: Citius Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Citius Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
7.75% (14 Jan 2022)
End of year
7.50% (30 Dec 2022)
Change
-0.25 pp
High
10.26% (31 May 2022)
Low
6.12% (28 Feb 2022)
Average
7.57%
Highest days to cover
31.17 (15 Nov 2022)
SEC filings marked
8

Every report in 2022

Citius Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20227.75%10.02
31 Jan 20227.34%6.77
15 Feb 20226.89%8.3210-Q filed, results (8-K)
28 Feb 20226.12%6.18
15 Mar 20226.22%8.98
31 Mar 20226.38%6.28
14 Apr 20227.24%4.07
29 Apr 20229.06%4.78
13 May 20229.58%5.8510-Q filed, results (8-K)
31 May 202210.26%10.74
15 Jun 20229.99%13.44
30 Jun 20227.08%4.56
15 Jul 20227.15%22.62
29 Jul 20226.81%13.75
15 Aug 20226.76%11.3710-Q filed, results (8-K)
31 Aug 20226.90%20.16
15 Sep 20227.14%20.04
30 Sep 20227.60%15.20
14 Oct 20227.59%24.54
31 Oct 20227.36%25.32
15 Nov 20227.46%31.17
30 Nov 20227.80%26.32
15 Dec 20227.75%28.52
30 Dec 20227.50%11.8410-K filed, results (8-K)

See also: Citius Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.